The stock of Selecta Biosciences Inc. (NASDAQ:SELB) increased by $0.02 on Friday to finish at $1.14, up 1.79 percent. The last five days have seen an average of 1,043,780 shares of common stock traded. 13 times new highs were reached in the current year, with a gain of $0.0100. The average number of shares traded over the last 20 days was 827,250, while the average volume over the last 50 days totaled 1,048,160.
SELB stock appreciated 8.57% since last month. On 08/02/23, the company’s shares reached a one-month low of $1.0100. The stock touched a high of $2.20 on 02/14/23, after rallying from a low of $0.90 in 52 weeks. The price of SELB stock has risen by 0.88% or $0.0100 this year, reaching a new high 13 times. Still, the stock price is down -48.18% from the 52-week high.
Insider Transactions
SELB stock investors should be aware that Selecta Biosciences Inc. (SELB) stock had its last reported insider trading activity 235 days ago on Jan 05. On Jan 05, President and CEO Brunn Carsten sold 13,473 shares at $1.13 each. This transaction resulted in the insider making $15,214. On Jan 05, TRABER PETER G sold 3,465 shares at a price of US$1.13. After the transaction, the insider now owns 446,121 shares. Chief Scientific Officer Kishimoto Takashi Kei had earlier sold 3,392 shares on Jan 05 for $1.13 a share. The transaction was completed for $3,830.
Valuation Metrics
Beta for the stock is 1.10. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.53, the price-to-book (PB) ratio of 2.65.
Financial Health
For the three months ended June 29, Selecta Biosciences Inc.’s quick ratio was 4.20, while its current ratio was 4.20, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.21, and the total debt to equity ratio is 0.37. Selecta Biosciences Inc.’s EBITDA margin for the year ended June 29 was 14.96%, whereas its operating margin stood at -96.90% for the same period. Based on annual data, it had gross profit of $96.24 million and revenue of $110.78 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. SELB’s return on assets (ROA) during the last 12 months has been -21.90%. There was a 12.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -44.00%.
Earnings Surprise
According to Selecta Biosciences Inc.’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $5.25 million, while revenues fell by -648.0% to $5.94 million. It was predicted that Selecta Biosciences Inc.’s quarterly earnings would be -$0.07, but it ended up being -$0.08, beating the consensus by 12.50%. EBITDA was -$18.46 million for the quarter. At the end of Selecta Biosciences Inc.’s most recent quarter ended June 29, its liabilities totaled 74.06 million, while its total debt was $34.91 million. Equity owned by shareholders amounts to $153.43 million.
Technical Picture
Here’s a quick look at Selecta Biosciences Inc.’s (SELB) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 55.85%, suggesting the stock is Neutral, with a 63.77% historical volatility rate.
The stochastic %K and %D were 70.59% and 79.57% respectively, while the average true range (ATR) was 0.0681. Based on the 14-day stochastic reading of 70.59%, the RSI (14) reading is 53.88%. On the 9-day MACD Oscillator, the stock is at 0.0178, and the 14-day reading is at 0.0336.
Analyst Ratings
Selecta Biosciences Inc. (NASDAQ: SELB) was downgraded by SVB Securities to a a Market perform rating in its latest research report. The stock was previously rated as a an Outperform. Analysts have assigned Selecta Biosciences Inc. (SELB) an Buy rating. SELB is a stock that is recommended for selling by 0 brokerage firms, while 1 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 5 others recommend it as a buy.
What is SELB’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.00 and $5.00, with a median target price of $4.00. In analyzing these forecasts, the average price target given by analysts for Selecta Biosciences Inc. (SELB) is $3.50.
